Signal Events: Cell Signal Transduction and Its Inhibition in Cancer

Signal Events: Cell Signal Transduction and Its Inhibition in Cancer Eric K. Rowinsky Oncologist 2003; 8(Suppl 3): 5-17 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in clinical pharmacology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Recognize the importance of identifying new molecular targets for cancer therapy and how they relate to the development of novel therapeutic agents with high therapeutic indices and low toxicity. Explain the process of signal transduction (specifically the ErbB family of receptors and the mTOR pathways) and how it relates to cell growth, differentiation, and survival, and describe the effects of aberrations in signal transduction on the development of neoplasms. Describe some of the novel targeted therapies that have been developed and explain the mechanisms by which signal transduction inhibitors inhibit tumor growth and induce tumor regression in patients with cancer. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Click Here to return to the complete course listing of Penetrating Insights: Crossing the Cancer Cell Membrane to Improve Clinical Outcomes.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Dec. 12, 2003 Most Recent Review: June 10, 2005* Most Recent Update: Dec. 12, 2003 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.